

Summary Report of Financial Results for the 3rd Quarter of FY ended December 2012

November 9, 2012

Company Name: Carna Biosciences, Inc.
 Stock exchange listing: Osaka Securities Exchange (JASDAQ Glowth)
 Stock Code: 4572
 URL: <http://www.carnabio.com/english/>
 Representative: Kohichiro Yoshino, President
 Contact: Norio Aikawa, Director
 TEL +81-78-302-7039

(Rounding down to the nearest million yen)

1. Consolidated results for the 3rd quarter of FY2012 (January 1, 2012 - September 30, 2012)

(1) Business Results (Consolidated) (% indicates increases or decreases from the previous 3rd quarter)

	Total Revenue		Operating income		Ordinary income		Net income	
	million yen	%	million yen	%	million yen	%	million yen	%
3 rd quarter of FY2012	370	-17.1	-364	-	-347	-	-354	-
3 rd quarter of FY2011	447	3.4	-287	-	-232	-	-250	-

	Net income per share	Net income per share (diluted)
	yen	yen
3 rd quarter of FY2012	-6038.23	-
3 rd quarter of FY2011	-4261.44	-

Note: Net income per share of 3rd quarter of FY2011 and 2012(Diluted): No statement - We had net loss per share even though we had diluted shares.

(2) Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio
	million yen	million yen	%
3 rd quarter of FY2012	903	668	74.0
FY2011	1,317	1,019	77.4

2. Cash Dividends

(criterion)	Dividends per share				
	End of 1 st quarter period	End of 2 nd quarter period	End of 3 rd quarter period	End of FY	FY
	yen	yen	yen	yen	yen
FY2011	-	0.00	-	0.00	0.00
FY2012	-	0.00	-		
FY2012 (forecast)				0.00	0.00

3. Consolidated forecast for FY2012 (January 1, 2012 - December 31, 2012)

(% indicates increases or decreases from the previous year)

	Total revenue		Operating income		Ordinary income		Net income		Net income per share
	million yen	%	million yen	%	million yen	%	million yen	%	yen
FY2012	728	22.9	-305	-	-289	-	-296	-	-5058.14

*Disclaimer regarding appropriate use of forecasts and related points of note

1. The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.
2. The forecasted net income per share above is calculated based on 58,710 issued shares.